Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
Clinicians have very limited options to treat triple-negative breast cancer (TNBC) due to the lack of effective targeted drugs. Recently, the findings of the mechanism underlying tumor-intrinsic immune escape have fueled a wave of studies into immunotherapy in breast cancer (BC). Compared with other...
Saved in:
Main Authors: | Xupeng Bai, Jie Ni, Julia Beretov, Peter Graham, Yong Li |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b70b5e3637074d7693e3d1e8c38ef8fc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
by: Peng Su, et al.
Published: (2021) -
Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
by: Alyssa Vito, et al.
Published: (2021) -
Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
by: Guangdi Chu, et al.
Published: (2021) -
Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer
by: Hongyuan Zhao, et al.
Published: (2021) -
Opportunities for metastatic triple negative breast cancer therapy
by: Inna P. Ganshina, et al.
Published: (2021)